RESUMO
In this paper, broadband dielectric spectroscopy (BDS) has been applied to study the molecular dynamics and crystallization kinetics of the antihyperlipidemic active pharmaceutical ingredient (API), gemfibrozil (GEM), as well as its deuterated (dGEM) and methylated (metGEM) derivatives, characterized by different types and strengths of intermolecular interactions. Moreover, calorimetric and infrared measurements have been carried out to characterize the thermal properties of examined samples and to probe a change in the H-bonding pattern in GEM, respectively. We found that the dielectric spectra of all examined compounds, collected below the glass transition temperature (Tg), reveal the presence of two secondary relaxations (ß, γ). According to the coupling model (CM) predictions, it was assumed that the slower process (ß) is of JG type, whereas the faster one (γ) has an intramolecular origin. Interestingly, the extensive crystallization kinetics measurements performed after applying two paths, i.e., the standard procedure (cooling and subsequently heating up to the appropriate temperature, Tc), as well as annealing at two temperatures in the vicinity of Tg and further heating up to Tc, showed that the annealing increases the crystallization rate in the case of native API, while the thermal history of the sample has no significant impact on the pace of this process in the two derivatives of GEM. Analysis of the dielectric strength (Δε) of the α-process during annealing, together with the results of Fourier transform infrared spectroscopy (FTIR) measurements, suggested that the reorganization within dimeric structures formed between the GEM molecules is responsible for the observed behavior. Importantly, our results differ from those obtained by Tominaka et al. (Tominaka, S.; Kawakami, K.; Fukushima, M.; Miyazaki, A.Physical Stabilization of Pharmaceutical Glasses Based on Hydrogen Bond Reorganization under Sub-Tg Temperature Mol. Pharm. 2017 14 264 273 10.1021/acs.molpharmaceut.6b00866.), who demonstrated that the sub-Tg annealing of ritonavir (RTV), which is able to form extensive supramolecular hydrogen bonds, protects this active substance against crystallization. Therefore, based on these contradictory reports, one can hypothesize that materials forming H-bonded structures, characterized by varying architecture, may behave differently after annealing in the vicinity of the glass transition temperature.
Assuntos
Dimerização , Genfibrozila/análogos & derivados , Genfibrozila/química , Vidro/química , Hipolipemiantes/química , Temperatura de Transição , Absorção Fisico-Química , Varredura Diferencial de Calorimetria , Cristalização/métodos , Espectroscopia Dielétrica/métodos , Inibidores da Protease de HIV/química , Ligação de Hidrogênio , Cinética , Simulação de Dinâmica Molecular , Transição de Fase , Ritonavir/química , Espectroscopia de Infravermelho com Transformada de Fourier/métodosRESUMO
Gemfibrozil is a fibrate drug used widely for dyslipidemia associated with atherosclerosis. Clinically, both gemfibrozil and its phase II metabolite gemfibrozil 1-O-ß-glucuronide (gem-glu) are involved in drug-drug interaction (DDI). But the DDI risk caused by gem-glu between human and mice has not been compared. In this study, six volunteers were recruited and took a therapeutic dose of gemfibrozil for 3 days for examination of the gemfibrozil and gem-glu level in human. Male mice were fed a gemfibrozil diet (0.75%) for 7 days, following which a cocktail-based inhibitory DDI experiment was performed. Plasma samples and liver tissues from mice were collected for determination of gemfibrozil, gem-glu concentration and cytochrome p450 enzyme (P450) induction analysis. In human, the molar ratio of gem-glu/gemfibrozil was 15% and 10% at the trough concentration and the concentration at 1.5 h after the 6th dose. In contrast, this molar ratio at steady state in mice was 91%, demonstrating a 6- to 9-fold difference compared with that in human. Interestingly, a net induction of P450 activity and in vivo inductive DDI potential in mice was revealed. The P450 activity was not inhibited although the gem-glu concentration was high. These data suggested species difference of relative gem-glu exposure between human and mice, as well as a net inductive DDI potential of gemfibrozil in mouse model.
Assuntos
Indutores das Enzimas do Citocromo P-450/farmacocinética , Sistema Enzimático do Citocromo P-450/efeitos dos fármacos , Genfibrozila/análogos & derivados , Glucuronatos/farmacocinética , Hipolipemiantes/farmacocinética , Adulto , Animais , Indutores das Enzimas do Citocromo P-450/administração & dosagem , Indutores das Enzimas do Citocromo P-450/farmacologia , Sistema Enzimático do Citocromo P-450/metabolismo , Interações Medicamentosas , Genfibrozila/farmacocinética , Genfibrozila/farmacologia , Glucuronatos/farmacologia , Humanos , Hipolipemiantes/administração & dosagem , Hipolipemiantes/farmacologia , Fígado/metabolismo , Masculino , Camundongos , Especificidade da Espécie , Fatores de Tempo , Adulto JovemRESUMO
INTRODUCTION: Cytochrome P450 (CYP) 2C8 is a drug metabolizing enzyme of major importance. The lipid-lowering drug gemfibrozil has been identified as a strong inhibitor of CYP2C8 in vivo. This effect is due to mechanism-based inhibition of CYP2C8 by gemfibrozil 1-O-ß-glucuronide. In vivo, gemfibrozil is a fairly selective CYP2C8 inhibitor, which lacks significant inhibitory effect on other CYP enzymes. Gemfibrozil can, however, have a smaller but clinically meaningful inhibitory effect on membrane transporters, such as organic anion transporting polypeptide 1B1 and organic anion transporter 3. Areas covered: This review describes the inhibitory effects of gemfibrozil on CYP enzymes and membrane transporters. The clinical drug interactions caused by gemfibrozil and the different mechanisms contributing to the interactions are reviewed in detail. Expert opinion: Gemfibrozil is a useful probe inhibitor of CYP2C8 in vivo, but its effect on membrane transporters has to be taken into account in study design and interpretation. Moreover, gemfibrozil could be used to boost the pharmacokinetics of CYP2C8 substrate drugs. Identification of gemfibrozil 1-O-ß-glucuronide as a potent mechanism-based inhibitor of CYP2C8 has led to recognition of glucuronide metabolites as perpetrators of drug-drug interactions. Recently, also acyl glucuronide metabolites of clopidogrel and deleobuvir have been shown to strongly inhibit CYP2C8.
Assuntos
Inibidores do Citocromo P-450 CYP2C8/farmacologia , Genfibrozila/farmacologia , Proteínas de Membrana Transportadoras/efeitos dos fármacos , Citocromo P-450 CYP2C8/efeitos dos fármacos , Inibidores do Citocromo P-450 CYP2C8/metabolismo , Interações Medicamentosas , Genfibrozila/análogos & derivados , Genfibrozila/metabolismo , Glucuronatos/metabolismo , Glucuronatos/farmacologia , Humanos , Hipolipemiantes/metabolismo , Hipolipemiantes/farmacologiaRESUMO
PURPOSE: Quantitative prediction of complex drug-drug interactions (DDIs) is challenging. Repaglinide is mainly metabolized by cytochrome-P-450 (CYP)2C8 and CYP3A4, and is also a substrate of organic anion transporting polypeptide (OATP)1B1. The purpose is to develop a physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics and DDIs of repaglinide. METHODS: In vitro hepatic transport of repaglinide, gemfibrozil and gemfibrozil 1-O-ß-glucuronide was characterized using sandwich-culture human hepatocytes. A PBPK model, implemented in Simcyp (Sheffield, UK), was developed utilizing in vitro transport and metabolic clearance data. RESULTS: In vitro studies suggested significant active hepatic uptake of repaglinide. Mechanistic model adequately described repaglinide pharmacokinetics, and successfully predicted DDIs with several OATP1B1 and CYP3A4 inhibitors (<10% error). Furthermore, repaglinide-gemfibrozil interaction at therapeutic dose was closely predicted using in vitro fraction metabolism for CYP2C8 (0.71), when primarily considering reversible inhibition of OATP1B1 and mechanism-based inactivation of CYP2C8 by gemfibrozil and gemfibrozil 1-O-ß-glucuronide. CONCLUSIONS: This study demonstrated that hepatic uptake is rate-determining in the systemic clearance of repaglinide. The model quantitatively predicted several repaglinide DDIs, including the complex interactions with gemfibrozil. Both OATP1B1 and CYP2C8 inhibition contribute significantly to repaglinide-gemfibrozil interaction, and need to be considered for quantitative rationalization of DDIs with either drug.
Assuntos
Carbamatos/farmacocinética , Genfibrozila/farmacocinética , Hepatócitos/metabolismo , Hipoglicemiantes/farmacocinética , Hipolipemiantes/farmacocinética , Piperidinas/farmacocinética , Hidrocarboneto de Aril Hidroxilases/antagonistas & inibidores , Hidrocarboneto de Aril Hidroxilases/metabolismo , Transporte Biológico Ativo/efeitos dos fármacos , Carbamatos/farmacologia , Linhagem Celular , Citocromo P-450 CYP2C8 , Interações Medicamentosas , Genfibrozila/análogos & derivados , Genfibrozila/farmacologia , Hepatócitos/efeitos dos fármacos , Humanos , Hipoglicemiantes/farmacologia , Hipolipemiantes/química , Hipolipemiantes/farmacologia , Transportador 1 de Ânion Orgânico Específico do Fígado , Modelos Biológicos , Transportadores de Ânions Orgânicos/antagonistas & inibidores , Transportadores de Ânions Orgânicos/metabolismo , Piperidinas/farmacologiaRESUMO
A new series of gemfibrozil analogues conjugated with α-asarone, trans-stilbene, chalcone, and their bioisosteric modifications were synthesized and evaluated to develop PPARα agonists. In this attempt, we have removed the methyls on the phenyl ring of gemfibrozil and introduced the above scaffolds in para position synthesizing two series of derivatives, keeping the dimethylpentanoic skeleton of gemfibrozil unaltered or demethylated. Four compounds exhibited good activation of the PPARα receptor and were also screened for their activity on PPARα-regulated gene CPT1A.
Assuntos
Carnitina O-Palmitoiltransferase/genética , Ácidos Graxos/metabolismo , Genfibrozila/análogos & derivados , Genfibrozila/farmacologia , PPAR alfa/agonistas , PPAR alfa/metabolismo , Células Hep G2 , Humanos , Regulação para Cima/efeitos dos fármacosRESUMO
Combination therapy of fibrates and nicotinic acid has been reported to be synergistic. Herein, we describe a covalent codrug of gemfibrozil (GEM) and nicotinic acid (NA) that was synthesized and characterized by (1)H NMR, (13)C NMR, FT-IR, MS analysis and elemental analysis. A validated HPLC method was developed that allows for the accurate quantitative determination of the codrug and its hydrolytic products that are formed during the in vitro chemical and enzymatic hydrolysis. The physico-chemical properties of codrug were improved compared to its parent drugs in term of water solubility and partition coefficient. The kinetics of hydrolysis of the codrug was studied using accelerated hydrolysis experiments at high temperatures in aqueous phosphate buffer solution in pH 1.2, 6.8 and 7.4. Using the Arrhenius equation, the extrapolated half-life at 37°C were 289 days at pH 1.2 for the codrug and 130 and 20,315 days at pH 6.8 for the codrug and gemfibrozil 2-hydroxyethyl ester (GHEE), respectively. The shortest half-lives were at pH 7.4; 42 days for the codrug and 5837 days for GHEE, respectively. The hydrolysis of the latter was studied, alone, at 80°C and pH 1.2 and compared to its hydrolysis when it is produced from the codrug using similar conditions. The k(obs) was found in both cases to be 1.60×10(-3)h(-1). The half-lives in plasma were 35.24 min and 26.75 h for the codrug and GHEE, respectively. With regard to liver homogenate, the hydrolysis half-lives were 1.96 min and 48.13 min for the codrug and GHEE, respectively. It can be expected that in vivo, the codrug will liberate NA immediately in plasma then GEM will be liberated from its 2-hydroxyethyl ester in the liver.
Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Ésteres/síntese química , Genfibrozila/análogos & derivados , Niacina , Ácidos Nicotínicos/síntese química , Ácidos Nicotínicos/farmacocinética , Pró-Fármacos/síntese química , Ésteres/sangue , Ésteres/metabolismo , Genfibrozila/sangue , Genfibrozila/síntese química , Genfibrozila/metabolismo , Genfibrozila/farmacocinética , Meia-Vida , Humanos , Concentração de Íons de Hidrogênio , Hidrólise , Hiperlipidemias/patologia , Cinética , Fígado/enzimologia , Espectroscopia de Ressonância Magnética , Espectrometria de Massas , Niacina/sangue , Niacina/síntese química , Niacina/metabolismo , Plasma/enzimologia , Pró-Fármacos/análise , Pró-Fármacos/metabolismo , Solubilidade , Espectroscopia de Infravermelho com Transformada de Fourier , TemperaturaRESUMO
To study the time to onset of mechanism-based inactivation of cytochrome P450 (CYP) 2C8 by gemfibrozil in vivo, we conducted a randomized five-phase crossover study in 10 healthy volunteers. In one phase the volunteers ingested 0.25 mg of repaglinide alone (control), and in the other phases they received 600 mg of gemfibrozil 0-6 h prior to the repaglinide dose. When gemfibrozil was taken 0, 1, 3, or 6 h before repaglinide, the geometric mean ratio relative to control (90% confidence interval (CI)) of repaglinide area under the plasma concentration-time curve (AUC(0-∞)) was 5.0-fold (4.3-5.7-fold), 6.3-fold (5.4-7.5-fold), 6.6-fold (5.6-7.7-fold), and 5.4-fold (4.8-6.1-fold), respectively (P < 0.001 vs. control). The geometric mean ratio relative to control (90% CI) of the maximum plasma concentration (C(max)) of the CYP2C8-mediated metabolite M4 was 1.0-fold (0.8-1.3-fold), 0.10-fold (0.06-0.17-fold, P < 0.001), 0.06-fold (0.04-0.10-fold, P < 0.001), and 0.09-fold (0.05-0.14-fold, P < 0.001), respectively. The strong inactivation of CYP2C8, evident as soon as 1 h after gemfibrozil dosing, has implications in clinical practice and in studies with gemfibrozil as a CYP2C8 model inhibitor.
Assuntos
Hidrocarboneto de Aril Hidroxilases/metabolismo , Carbamatos/farmacocinética , Genfibrozila/farmacologia , Hipoglicemiantes/farmacocinética , Piperidinas/farmacocinética , Adulto , Área Sob a Curva , Hidrocarboneto de Aril Hidroxilases/antagonistas & inibidores , Estudos Cross-Over , Citocromo P-450 CYP2C8 , Feminino , Genfibrozila/análogos & derivados , Genfibrozila/farmacocinética , Glucuronatos/farmacologia , Humanos , Masculino , Fatores de TempoRESUMO
PURPOSE: Gemfibrozil, a strong inhibitor of cytochrome P450 (CYP) 2C8 in vivo, was recently found to markedly increase the plasma concentrations of montelukast in humans. Like montelukast, zafirlukast is a substrate of CYP2C9 and CYP3A4 and a potent inhibitor of CYP2C8 in vitro. To investigate the contribution of CYP2C8 to the metabolism of zafirlukast in vivo, we studied the effect of gemfibrozil on the pharmacokinetics of zafirlukast. METHODS: Ten healthy subjects in a randomized cross-over study took gemfibrozil 600 mg or placebo twice daily for 5 days, and on day 3, a single oral dose of 20 mg zafirlukast. The plasma concentrations of zafirlukast were measured for 72 h postdose. RESULTS: The mean total area under the plasma concentration-time curve of zafirlukast during the gemfibrozil phase was 102% (geometric mean ratio; 95% confidence interval 89-116%) of that during the placebo phase. Furthermore, there were no statistically significant differences in the peak plasma concentration, time of peak concentration, or elimination half-life of zafirlukast between the phases. CONCLUSIONS: Gemfibrozil has no effect on the pharmacokinetics of zafirlukast, indicating that CYP2C8 does not play a significant role in the elimination of zafirlukast.
Assuntos
Hidrocarboneto de Aril Hidroxilases/antagonistas & inibidores , Genfibrozila/farmacologia , Compostos de Tosil/farmacocinética , Adulto , Hidrocarboneto de Aril Hidroxilases/metabolismo , Estudos Cross-Over , Citocromo P-450 CYP2C8 , Interações Medicamentosas , Feminino , Genfibrozila/análogos & derivados , Genfibrozila/sangue , Genfibrozila/farmacocinética , Glucuronatos/farmacocinética , Humanos , Indóis , Masculino , Fenilcarbamatos , Sulfonamidas , Compostos de Tosil/sangue , Adulto JovemRESUMO
Gemfibrozil 1-O-beta-glucuronide is a mechanism-based inhibitor of cytochrome P450 2C8. We studied the recovery of CYP2C8 activity after discontinuation of gemfibrozil treatment using repaglinide as a probe drug, to estimate the in vivo turnover half-life of CYP2C8. In a randomized five-phase crossover study, nine healthy volunteers ingested 0.25 mg of repaglinide alone or after different time intervals after a 3-day treatment with 600 mg of gemfibrozil twice daily. The area under the plasma concentration-time curve (AUC) from time 0 to infinity of repaglinide was 7.6-, 2.9-, 1.4- and 1.0-fold compared with the control phase when it was administered 1, 24, 48, or 96 h after the last gemfibrozil dose, respectively (P < 0.001 versus control for 1, 24, and 48 h after gemfibrozil). Thus, a strong CYP2C8 inhibitory effect persisted even after gemfibrozil and gemfibrozil 1-O-beta-glucuronide concentrations had decreased to less than 1% of their maximum (24-h dosing interval). In addition, the metabolite to repaglinide AUC ratios indicated that significant (P < 0.05) inhibition of repaglinide metabolism continued up to 48 h after gemfibrozil administration. Based on the recovery of repaglinide oral clearance, the in vivo turnover half-life of CYP2C8 was estimated to average 22 +/- 6 h (mean +/- S.D.). In summary, CYP2C8 activity is recovered gradually during days 1 to 4 after gemfibrozil discontinuation, which should be considered when CYP2C8 substrate dosing is planned. The estimated CYP2C8 half-life will be useful for in vitro-in vivo extrapolations of drug-drug interactions involving induction or mechanism-based inhibition of CYP2C8.
Assuntos
Hidrocarboneto de Aril Hidroxilases/antagonistas & inibidores , Hidrocarboneto de Aril Hidroxilases/metabolismo , Carbamatos/farmacocinética , Inibidores Enzimáticos/administração & dosagem , Genfibrozila/administração & dosagem , Hipoglicemiantes/farmacocinética , Hipolipemiantes/administração & dosagem , Sondas Moleculares/farmacocinética , Piperidinas/farmacocinética , Administração Oral , Área Sob a Curva , Hidrocarboneto de Aril Hidroxilases/genética , Biotransformação , Glicemia/efeitos dos fármacos , Carbamatos/administração & dosagem , Carbamatos/sangue , Estudos Cross-Over , Citocromo P-450 CYP2C8 , Interações Medicamentosas , Inibidores Enzimáticos/sangue , Inibidores Enzimáticos/farmacocinética , Feminino , Genfibrozila/análogos & derivados , Genfibrozila/sangue , Genfibrozila/farmacocinética , Genótipo , Glucuronatos/sangue , Glucuronatos/farmacocinética , Meia-Vida , Humanos , Hipoglicemiantes/administração & dosagem , Hipoglicemiantes/sangue , Hipolipemiantes/sangue , Hipolipemiantes/farmacocinética , Transportador 1 de Ânion Orgânico Específico do Fígado , Masculino , Modelos Biológicos , Sondas Moleculares/administração & dosagem , Sondas Moleculares/sangue , Transportadores de Ânions Orgânicos/genética , Transportadores de Ânions Orgânicos/metabolismo , Fenótipo , Piperidinas/administração & dosagem , Piperidinas/sangue , Adulto JovemRESUMO
Gemfibrozil-1-O-beta-glucuronide (GEM-1-O-gluc), a major metabolite of the antihyperlipidemic drug gemfibrozil, is a mechanism-based inhibitor of P450 2C8 in vitro, and this irreversible inactivation may lead to clinical drug-drug interactions between gemfibrozil and other P450 2C8 substrates. In light of this in vitro finding and the observation that the glucuronide conjugate does not contain any obvious structural alerts, the current study was conducted to determine the potential site of GEM-1-O-gluc bioactivation and the subsequent mechanism of P450 2C8 inhibition (i.e., modification of apoprotein or heme). LC/MS analysis of a reaction mixture containing recombinant P450 2C8 and GEM-1-O-gluc revealed that the substrate was covalently linked to the heme prosthetic heme group during catalysis. A combination of mass spectrometry and deuterium isotope effects revealed that a benzylic carbon on the 2',5'-dimethylphenoxy group of GEM-1-O-gluc was covalently bound to the heme of P450 2C8. The regiospecificity of substrate addition to the heme group was not confirmed experimentally, but computational modeling experiments indicated that the gamma-meso position was the most likely site of modification. The metabolite profile, which consisted of two benzyl alcohol metabolites and a 4'-hydroxy-GEM-1-O-gluc metabolite, indicated that oxidation of GEM-1-O-gluc was limited to the 2',5'-dimethylphenoxy group. These results are consistent with an inactivation mechanism wherein GEM-1-O-gluc is oxidized to a benzyl radical intermediate, which evades oxygen rebound, and adds to the gamma-meso position of heme. Mechanism-based inhibition of P450 2C8 can be rationalized by the formation of the GEM-1-O-gluc-heme adduct and the consequential restriction of additional substrate access to the catalytic iron center.
Assuntos
Hidrocarboneto de Aril Hidroxilases/metabolismo , Genfibrozila/análogos & derivados , Glucuronatos/química , Heme/química , Alquilação , Hidrocarboneto de Aril Hidroxilases/antagonistas & inibidores , Domínio Catalítico , Cromatografia Líquida de Alta Pressão , Simulação por Computador , Citocromo P-450 CYP2C8 , Genfibrozila/química , Genfibrozila/metabolismo , Genfibrozila/farmacologia , Genfibrozila/toxicidade , Glucuronatos/farmacologia , Glucuronatos/toxicidade , Humanos , Hipolipemiantes/metabolismo , Espectrometria de Massas , Oxirredução , Proteínas Recombinantes/antagonistas & inibidores , Proteínas Recombinantes/metabolismoRESUMO
Repaglinide is metabolized by cytochrome P450 (CYP) 2C8 and 3A4. Gemfibrozil has the effect of increasing the area under the concentration-time curve (AUC) of repaglinide eightfold. We studied the effect of dosing interval on the extent of the gemfibrozil-repaglinide interaction. In a randomized five-phase crossover study, 10 healthy volunteers ingested 0.25 mg repaglinide, with or without gemfibrozil pretreatment. Plasma repaglinide, gemfibrozil, their metabolites, and blood glucose were measured. When the last dose of 600 mg gemfibrozil was ingested simultaneously with repaglinide, or 3, 6, or 12 h before, it increased the AUC(0-infinity) of repaglinide 7.0-, 6.5-, 6.2- and 5.0-fold, respectively (P < 0.001). The peak repaglinide concentration increased approximately twofold (P < 0.001), and the half-life was prolonged from 1.2 h to 2-3 h (P < 0.001) during all the gemfibrozil phases. The drug interaction effects persisted at least 12 h after gemfibrozil was administered, although plasma gemfibrozil and gemfibrozil 1-O-beta-glucuronide concentrations were only 5 and 10% of their peak values, respectively. The long-lasting interaction is likely caused by mechanism-based inhibition of CYP2C8 by gemfibrozil glucuronide.
Assuntos
Glicemia/efeitos dos fármacos , Carbamatos/farmacocinética , Genfibrozila/farmacologia , Hipoglicemiantes/farmacocinética , Hipolipemiantes/farmacologia , Piperidinas/farmacocinética , Adulto , Área Sob a Curva , Hidrocarboneto de Aril Hidroxilases/antagonistas & inibidores , Hidrocarboneto de Aril Hidroxilases/genética , Citocromo P-450 CYP2C8 , Interações Medicamentosas , Feminino , Genfibrozila/análogos & derivados , Genfibrozila/sangue , Genfibrozila/farmacocinética , Glucuronatos/sangue , Glucuronatos/farmacocinética , Meia-Vida , Humanos , Hipolipemiantes/sangue , Hipolipemiantes/farmacocinética , MasculinoRESUMO
The excitation-contraction coupling in skeletal muscle is modulated by nitric oxide via redox status modification of ryanodine receptor on sarcoplasmic reticulum during events that lead to muscle contraction. We have synthesized a derivative of antilipidemic drug, gemfibrozil, in which a NO-donor furoxan moiety is joined to the fibrate by an ester linkage. Aim of the present study was to determine if the NO released from the above compound is capable of influencing the NO-sensible E-C coupling steps in skeletal muscle and if this effect could be potentially utilised for physiopathological studies and pharmaceutical applications. To obtain this goal we decided to study some of the excitation-contraction mechanisms in the presence of NO-releasing derivative of gemfibrozil in skeletal muscle C2C12 cell line.
Assuntos
Ésteres/farmacologia , Genfibrozila/análogos & derivados , Genfibrozila/farmacologia , Contração Muscular/efeitos dos fármacos , Fibras Musculares Esqueléticas/efeitos dos fármacos , Músculo Esquelético/efeitos dos fármacos , Doadores de Óxido Nítrico/farmacologia , Oxidiazóis/farmacologia , Animais , Linhagem Celular , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Ésteres/síntese química , Ésteres/química , Genfibrozila/síntese química , Genfibrozila/química , Camundongos , Estrutura Molecular , Contração Muscular/fisiologia , Fibras Musculares Esqueléticas/citologia , Fibras Musculares Esqueléticas/fisiologia , Músculo Esquelético/citologia , Músculo Esquelético/fisiologia , Óxido Nítrico/metabolismo , Doadores de Óxido Nítrico/síntese química , Doadores de Óxido Nítrico/química , Oxidiazóis/síntese química , Oxidiazóis/químicaRESUMO
Gemfibrozil more potently inhibits CYP2C9 than CYP2C8 in vitro, and yet the opposite inhibitory potency is observed in the clinic. To investigate this apparent paradox, we evaluated both gemfibrozil and its major metabolite, an acyl-glucuronide (gemfibrozil 1-O-beta-glucuronide) as direct-acting and metabolism-dependent inhibitors of the major drug-metabolizing cytochrome P450 enzymes (CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4) in human liver microsomes. Gemfibrozil most potently inhibited CYP2C9 (IC50 of 30 microM), whereas gemfibrozil glucuronide most potently inhibited CYP2C8 (IC50 of 24 microM). Unexpectedly, gemfibrozil glucuronide, but not gemfibrozil, was found to be a metabolism-dependent inhibitor of CYP2C8 only. The IC50 for inhibition of CYP2C8 by gemfibrozil glucuronide decreased from 24 microM to 1.8 microM after a 30-min incubation with human liver microsomes and NADPH. Inactivation of CYP2C8 by gemfibrozil glucuronide required NADPH, and proceeded with a K(I) (inhibitor concentration that supports half the maximal rate of enzyme inactivation) of 20 to 52 microM and a k(inact) (maximal rate of inactivation) of 0.21 min(-1). Potent inhibition of CYP2C8 was also achieved by first incubating gemfibrozil with alamethicin-activated human liver microsomes and UDP-glucuronic acid (to form gemfibrozil glucuronide), followed by a second incubation with NADPH. Liquid chromatography-tandem mass spectrometry analysis established that human liver microsomes and recombinant CYP2C8 both convert gemfibrozil glucuronide to a hydroxylated metabolite, with oxidative metabolism occurring on the dimethylphenoxy moiety (the group furthest from the glucuronide moiety). The results described have important implications for the mechanism of the clinical interaction reported between gemfibrozil and CYP2C8 substrates such as cerivastatin, repaglinide, rosiglitazone, and pioglitazone.
Assuntos
Hidrocarboneto de Aril Hidroxilases/antagonistas & inibidores , Genfibrozila/farmacologia , Glucuronídeos/metabolismo , Alameticina/metabolismo , Alameticina/farmacologia , Hidrocarboneto de Aril Hidroxilases/metabolismo , Cromatografia Líquida de Alta Pressão/métodos , Citocromo P-450 CYP2C8 , Relação Dose-Resposta a Droga , Interações Medicamentosas , Genfibrozila/análogos & derivados , Genfibrozila/metabolismo , Glucuronatos/metabolismo , Glucuronatos/farmacologia , Humanos , Hipolipemiantes/metabolismo , Hipolipemiantes/farmacologia , Espectrometria de Massas/métodos , Microssomos Hepáticos/efeitos dos fármacos , Microssomos Hepáticos/metabolismo , Uridina Difosfato Ácido Glucurônico/metabolismo , Uridina Difosfato Ácido Glucurônico/farmacologiaRESUMO
Two types of polymer-drug conjugates were synthesized starting from styrene-maleic acid anhydride copolymer (SMA). Fenoprofen and gemfibrozil were chosen as model drugs because of their short plasma half lives. Both drugs were first converted to their 2-aminoethylamides, which possess free amino groups capable of reacting with SMA anhydride rings. By modifying the degree and type of substitution, lipophilic and hydrophilic conjugates were obtained. Drug loading in the conjugates was between 17 and 47%.
Assuntos
Anti-Inflamatórios não Esteroides/síntese química , Fenoprofeno/análogos & derivados , Fenoprofeno/síntese química , Genfibrozila/análogos & derivados , Genfibrozila/síntese química , Hipolipemiantes/síntese química , Anti-Inflamatórios não Esteroides/química , Cromatografia em Camada Fina , Fenoprofeno/química , Genfibrozila/química , Hipolipemiantes/química , Maleatos/química , Pró-Fármacos , Espectrofotometria Infravermelho , Espectrofotometria Ultravioleta , Espectroscopia de Infravermelho com Transformada de Fourier , Estirenos/químicaRESUMO
Foods and complementary medicines contain phytoestrogenic isoflavones such as genistein, which undergo hepatic glucuronidation and excretion into bile and can potentially interfere with the hepatic elimination of other compounds. To investigate this potential, livers from Sprague-Dawley rats were perfused in single-pass mode with preformed gemfibrozil 1-O-acyl glucuronide (GG) (1 microM, n = 12) for 60 min followed by a 30-min washout phase, or with gemfibrozil (1 microM, n = 10) for 120 min. Half of each group of livers were co-perfused with genistein (10 microM) throughout the experiment. Perfusate and bile were analyzed for GG and gemfibrozil by HPLC. Co-perfusion with genistein significantly (P< 0.05) decreased the biliary extraction ratio of preformed GG from a mean of 0.82 to 0.65 and the first-order rate constant for transport of GG into bile from 0.054 +/- 0.010 to 0.032 +/- 0.008 min(-1), but increased the first-order rate constant for sinusoidal efflux of GG from 0.128 +/- 0.023 to 0.227 +/- 0.078 min(-1). Co-perfusion with genistein also significantly decreased the biliary extraction ratio of hepatically generated GG from 0.95 +/- 0.01 to 0.83 +/- 0.05. The findings confirm that genistein increases the potential for hepatic and systemic exposure to hepatically generated glucuronides, which may be important for patients on conventional drugs who consume isoflavones.
Assuntos
Inibidores Enzimáticos/farmacologia , Genfibrozila/análogos & derivados , Genfibrozila/farmacocinética , Genisteína/farmacologia , Glucuronatos/farmacocinética , Animais , Quimioterapia do Câncer por Perfusão Regional , Interações Medicamentosas , Cinética , Fígado/química , Masculino , Técnicas de Cultura de Órgãos , Ratos , Ratos Sprague-DawleyRESUMO
PURPOSE: Phase II metabolism involves the conjugation of a polar moiety, such as sulfate or glucuronic acid, to a (relatively) nonpolar xenobiotic. Although it might be expected that such conjugates may exhibit amphiphilic character (e.g., surface activity and potential to form micelles), no detailed study of the micellization characteristics of any drug-glucuronide conjugates has yet been reported. Therefore, the aim of this study was to investigate the solution behavior and amphiphilic characteristics of gemfibrozil 1-O-beta glucuronide (GG), a model drug-glucuronide conjugate. METHODS: Crude GG was extracted from the urine of volunteers dosed with 600 mg of gemfibrozil, and this material was then purified by reversed-phase high-performance liquid chromatography to yield a white solid. The amphiphilic properties of GG within the bulk aqueous phase were studied by isothermal titration microcalorimetry and 1H-NMR spectrometry, whereas those at the aqueous/air interface were studied by surface tensiometry. RESULTS: The results of each independent analytical technique were consistent with GG in aqueous solution exhibiting amphiphilic properties typical of a hydrophilic surfactant. The titration microcalorimetry and 1H-NMR spectrometry data were in excellent agreement with each other, yielding critical micellization concentrations (cmc) for GG in 0.1 M acetate buffer of 18.1 +/- 0.4 mM and 18.3 +/- 0.3 mM, respectively. The profile and results of the surface tension measurements were consistent with GG localizing at the aqueous/air interface. CONCLUSIONS: These results confirm the hypothesis that a glucuronide conjugate of a relatively nonpolar xenobiotic, such as gemfibrozil, behaves as an amphiphile in aqueous solution. The implications of this observation include a likely basis for the previously observed concentration-dependence in the degradation rate of the acyl glucuronides of 2-phenylpropionic acid, as well as identifying a possible broader contributory effect to the structural dependencies in biliary choleresis of different glucuronide conjugates of xenobiotics.
Assuntos
Genfibrozila/análogos & derivados , Genfibrozila/química , Glucuronatos/química , Calorimetria , Química Farmacêutica , Composição de Medicamentos , Concentração de Íons de Hidrogênio , Espectroscopia de Ressonância Magnética , Micelas , Soluções Farmacêuticas/química , Tensão Superficial , ÁguaRESUMO
A series of gemfibrozil analogues with a thiourea moiety embedded in the side chain was prepared and evaluated as HDL-elevating agents. Derivatives 8b, 9b, 9c, and 9d were found to be approximately as effective as gemfibrozil (1) for HDL cholesterol elevation.
Assuntos
Genfibrozila/análogos & derivados , Hipolipemiantes/síntese química , Lipoproteínas HDL/efeitos dos fármacos , Administração Oral , Animais , Apolipoproteína A-I/sangue , Apolipoproteína A-I/efeitos dos fármacos , Genfibrozila/síntese química , Genfibrozila/farmacologia , Hipolipemiantes/farmacologia , Lipoproteínas HDL/sangue , Masculino , Ratos , Ratos Sprague-Dawley , Relação Estrutura-Atividade , Tioureia/síntese química , Tioureia/farmacologiaRESUMO
The chiral analogues of gemfibrozil 5-(2,5-dimethylphenoxy)-2-methylpentanoic acid and 5-(2,5-dimethylphenoxy)-2-ethylpentanoic acid were synthesized in optically active form using (S)-4-(1-methylethyl)-2-oxazolidinone as chiral auxiliary. All compounds inhibit human platelet aggregation. From these data, one can surmise that all tested compounds and gemfibrozil act at the platelet level with different mechanism than that of ASA, even if with a different potency.
Assuntos
Plaquetas/efeitos dos fármacos , Genfibrozila/síntese química , Genfibrozila/farmacologia , Inibidores da Agregação Plaquetária/síntese química , Inibidores da Agregação Plaquetária/farmacologia , Genfibrozila/análogos & derivados , Humanos , Técnicas In Vitro , Estrutura Molecular , Relação Estrutura-AtividadeRESUMO
The synthesis and spectroscopic characterisation of various gemfibrozil esters 3 and amides 4 are described. In the first step gemfibrozil was reacted with N-1-benzotriazolecarboxylic acid chloride (1) yielding gemfibrozil benzotriazolide (2). Compound 2 readily reacted with alcohols and amines to form the corresponding esters 3 and amides 4, potential prodrugs of the well known hypolipaemic drug gemfibrozil. The quantitative structure property relationship (QSPR) was studied in the series of gemfibrozil esters and amides. The following topological descriptors and physicochemical parameters were used: Wiener number (W), connectivity index (l chi v), relative molecular mass (M(r)), van der Waals volume (Vw) and parameters of lipophilicity (log P and RM).
Assuntos
Genfibrozila/análogos & derivados , Genfibrozila/farmacologia , Hipolipemiantes/farmacologia , Algoritmos , Fenômenos Químicos , Físico-Química , Cromatografia em Camada Fina , Genfibrozila/química , Hipolipemiantes/química , Espectroscopia de Ressonância Magnética , Peso Molecular , Relação Quantitativa Estrutura-Atividade , Análise de Regressão , Espectrofotometria InfravermelhoRESUMO
Glucuronidation of carboxylic acid compounds results in the formation of electrophilic acyl glucuronides. Because of their polarity, carrier-mediated hepatic transport systems play an important role in determining both intra- and extrahepatic exposure to these reactive conjugates. We have previously shown that the hepatic membrane transport of 1-O-gemfibrozil-beta-D-glucuronide (GG) is carrier-mediated and inhibited by the organic anion dibromosulfophthalein. In this study, we examined the influence of 200 microM acetaminophen, acetaminophen glucuronide, and clofibric acid on the disposition of GG (3 microM) in the recirculating isolated perfused rat liver preparation. GG was taken up by the liver, excreted into bile, and hydrolyzed within the liver to gemfibrozil, which appeared in perfusate but not in bile. Mean +/- S. D. hepatic clearance, apparent intrinsic clearance, hepatic extraction ratio, and biliary excretion half-life of GG were 10.4 +/- 1.4 ml/min, 94.1 +/- 17.9 ml/min, 0.346 +/- 0.046, and 30.9 +/- 4.9 min, respectively, and approximately 73% of GG was excreted into bile. At the termination of the experiment (t = 90 min), the ratio of GG concentrations in perfusate, liver, and bile was 1:35:3136. Acetaminophen and acetaminophen glucuronide had no effect on the hepatic disposition of GG, suggesting relatively low affinities of acetaminophen conjugates for hepatic transport systems or the involvement of multiple transport systems for glucuronide conjugates. In contrast, clofibric acid increased the hepatic clearance, extraction ratio, and apparent intrinsic clearance of GG (P <.05) while decreasing its biliary excretion half-life (P <.05), suggesting an interaction between GG and hepatically generated clofibric acid glucuronide at the level of hepatic transport. However, the transporter protein(s) involved remains to be identified.